Eisai is a cash-cow oncology business racing the clock to turn Leqembi into a scalable, home-dosed Alzheimer’s franchise before Lenvima’s 2030 cliff hits.
Overview
Eisai is undergoing a high-stakes transformation from a diversified pharma anchored by mature oncology cash flows to a neurology specialist whose terminal value depends on Leqembi’s global commercialization. H1 FY2025 revenue rose ~4% YoY to ¥400.0B and operating profit grew 23.6% to ¥34.4B, but the company materially missed EPS (¥36.02 vs ¥50.12) due to the capital intensity of building the Leqembi diagnostic/treatment ecosystem and expanded US SG&A. Lenvima remains the funding engine (¥166.5B in H1), but a settled US generic entry date (July 2030) forces Leqembi to reach blockbuster scale by decade-end to avoid a structural revenue gap. Valuation (P/E ~26–28x) embeds an Alzheimer’s “option premium” and is sensitive to competitive pressure from Lilly’s Kisunla and to USD/JPY FX moves.